---
title: "HC Wainwright & Co. maintains Buy rating on Enliven Therapeutics, $73 price target"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/302274040.md"
description: "HC Wainwright & Co. maintained a Buy rating on Enliven Therapeutics with a $73 price target, implying 95.6% upside from the Oct 16 close of $37.32. The firm cites positive trial outlooks for the ENABLE-2 trial and strong comparative efficacy data for ELVN-001, which outperformed existing treatments in Phase 1 results."
datetime: "2026-10-19T10:27:52.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/302274040.md)
  - [en](https://longbridge.com/en/news/302274040.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/302274040.md)
generator: "portal-rs"
---

# HC Wainwright & Co. maintains Buy rating on Enliven Therapeutics, $73 price target

HC Wainwright & Co. maintained their Buy rating on Enliven Therapeutics's stock with a price target of $73.00.

The price target implies an upside of 95.6% from the Oct 16 close of $37.32.

**Key takeaways from the analyst note**

**Positive Trial Outlook**: Enliven Therapeutics is expected to initiate the ENABLE-2 trial, which has been deemed relatively de-risked due to alignment with the FDA on its design. The high probability of positive outcomes stems from encouraging results in previous trials for their product candidate ELVN-001, specifically targeting chronic myeloid leukemia.

**Strong Comparative Efficacy**: The preliminary data from the Phase 1 ENABLE trial demonstrate that relcobatinib (ELVN-001) achieved major molecular response rates that significantly outperformed existing treatments like bosutinib and asciminib. This positions Enliven's candidate as a potentially more effective option for patients, enhancing investor confidence in the company's future.

Explore more price target data and ratings for Enliven Therapeutics on the .

**Disclaimer**

Select reference data provided by Benzinga. This information is not a recommendation for what you should do personally and does not constitute investment advice.

### Related Stocks

- [ELVN.US](https://longbridge.com/en/quote/ELVN.US.md)
- [COCH.US](https://longbridge.com/en/quote/COCH.US.md)

## Related News & Research

- [Enliven Therapeutics Chief Medical Officer Helen Louise Collins reports sale of $234,203.1101 in common shares](https://longbridge.com/en/news/306180389.md)
- [ELVN: Second-line-plus phase III launch is imminent, with a potential early-2029 readout](https://longbridge.com/en/news/305860981.md)
- [Enliven Therapeutics Q3 net loss widens on higher R&D spend](https://longbridge.com/en/news/304533501.md)
- [Should FDA Trial Design Agreement Require Action From Enliven Therapeutics (ELVN) Investors?](https://longbridge.com/en/news/301454021.md)
- [Enliven Therapeutics aligns with FDA on Phase 3 ENABLE-2 trial design for relcobatinib in previously treated CML](https://longbridge.com/en/news/301071902.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**